Non-immune targeting of CXCR3 compromises mitochondrial function and suppresses tumor growth in glioblastoma

Travis Yui Hei Chan1, Bo Chen1, Wanjun Tang1

  • 1Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Cell Death Discovery
|April 4, 2025
PubMed

Insights

The chemokine receptor CXCR3 regulates mitochondrial function in glioblastoma (GBM) cells, impacting cancer growth. Targeting this CXCR3-mitochondrial axis offers a new therapeutic strategy for GBM.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Medicine

Background:

  • Chemokine receptors, like CXCR3, are known for immune cell roles.
  • Emerging research suggests non-immune functions, particularly in cancer.
  • The specific roles of CXCR3 in glioblastoma (GBM) require further elucidation.

Purpose of the Study:

  • To investigate the non-immune functions of CXCR3 in glioblastoma.
  • To determine the correlation between CXCR3 expression and GBM patient prognosis.
  • To elucidate the mechanism by which CXCR3 influences GBM cell behavior and tumor growth.

Main Methods:

  • Analysis of CXCR3 expression in relation to GBM grading and patient prognosis.
  • In vitro and in vivo experiments involving CXCR3 isoform ablation in GBM cells.
  • Transcriptomic profiling of tumor xenografts to identify molecular pathways affected by CXCR3.
  • Mitochondrial function assays, including membrane potential and reactive oxygen species production.
  • In vivo studies using the CXCR3 antagonist AMG487.

Main Results:

  • CXCR3 expression correlates with GBM grade, with CXCR3-A linked to poorer prognosis.
  • CXCR3 ablation impairs GBM cell proliferation, migration, and tumor growth.
  • CXCR3 localizes to the mitochondrial membrane, regulating mitochondrial homeostasis.
  • CXCR3 inhibition disrupts mitochondrial function, leading to depolarization and increased ROS.
  • STAT3 activation rescues viability in CXCR3-depleted cells, suggesting a STAT3-dependent mechanism.
  • AMG487 treatment reduces tumor growth and impairs mitochondrial function in GBM models.

Conclusions:

  • CXCR3 is a novel regulator of mitochondrial function in cancer cells.
  • The CXCR3-mitochondrial signaling axis represents a potential therapeutic target for GBM.
  • Targeting CXCR3 may offer a new strategy to combat glioblastoma growth and progression.